



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031

**THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

substitute for form 1449/PTO		<i>Complete if Known</i>	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/914,046
		Filing Date	October 1, 2001
		First Named Inventor	XU, Liang
		Art Unit	1644
		Examiner Name	DIBRINO, Marianne
Sheet	1	of	1
		Attorney Docket Number	2474.0010001/BJD/JKM

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

712306_1

Examiner Signature	/Marianne Dibrino/	Date Considered	04/08/2008
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	09/914,046
Filing Date	October 1, 2001
First Named Inventor	XU, Liang
Art Unit	1644
Examiner Name	DIBRINO, Marianne
Sheet	1 of 1
Attorney Docket Number	2474.0010001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/MD/	NPL70	Hamada, K., <i>et al.</i> , "Adenovirus-Mediated Transfer of HPV 16 E6/E7 Antisense RNA to Human Cervical Cancer Cells," <i>Gynecologic Oncology</i> 63:219-227, Academic Press, Inc. (1996)	
/MD/	NPL71	Hamada, K. <i>et al.</i> , "Growth Inhibition of Human Cervical Cancer Cells with the Recombinant Adenovirus <i>p53 in Vitro</i> ," <i>Gynecologic Oncology</i> 60:373-379, Academic Press, Inc. (1996)	
/MD/	NPL72	Database Medline, Accession No. NLM7621238, English language abstract for Zhang, W.W., <i>et al.</i> , "High-efficiency gene transfer and high-level expression of wild-type <i>p53</i> in human lung cancer cells mediated by recombinant adenovirus," <i>Cancer Gene Therapy</i> 1:5-13, Nature Publishing Group (1994)	
/MD/	NPL73	Copy of Non-Final Office Action for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed September 22, 2005	
/MD/	NPL74	Copy of Final Office Action for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed May 31, 2006	
/MD/	NPL75	Copy of Non-Final Office Action for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed December 5, 2006	
/MD/	NPL76	Copy of Interview Summary for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed July 27, 2007	
/MD/	NPL77	Copy of Final Office Action for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed July 27, 2007	
/MD/	NPL78	Copy of Interview Summary for U.S. Patent Application No. 10/113,927, inventors Chang <i>et al.</i> , mailed November 6, 2007	

712307_1

Examiner Signature	/Marianne Dibrino/	Date Considered	04/08/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.